TrialPloS one2010
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
Jeffrey R Currier et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
53 papers cite it
this paperpooled ittrialcites it